Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoldonrasib + daraxonrasib versus gemcitabine + nab-paclitaxel in first-line metastatic KRAS G12D-mutated pancreatic adenocarcinoma
NL-OMON61728Phase 3Not yet recruiting
- Sponsor
- Revolution Medicines
- Start
- Oct 2026
- Modality
- Small Molecules, Cyclic Peptides → Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in pancreatic adenocarcinoma (PDAC) comparing Zoldonrasib + daraxonrasib with Gemcitabine + nab-paclitaxel (2 arms). Primary endpoints: Progression-free survival and Overall survival. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
zoldonrasibdaraxonrasibgemcitabinepaclitaxel
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NL-OMON61728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61728.